

# CELLS, TISSUES, AND ORGANS SURVEILLANCE SYSTEM (CTOSS), 2020-2021

**CTOSS** monitors adverse events related to transplantation of cells, tissues, and organs in Canada.

**2011** The system started in 2011. Currently, it only covers tissue transplants. The [link](#) contains a detailed methodology of surveillance.

**30%** of tissues transplanted in Canada are monitored through four participating provinces in CTOSS.


**68,955** tissues were transplanted during 2011-2021.

**18,053** tissues were transplanted during 2020-2021.


**38** transplantation adverse events (TAEs\*) were reported during 2011-2021.

**12** TAEs were reported during 2020-2021. The incidence rate was 0.66 TAEs/1,000 grafts.

## TOTAL TISSUES TRANSPLANTED BASED ON TISSUE TYPES, CTOSS 2020-2021





## TISSUES INVOLVING ADVERSE EVENTS (N=38), CTOSS 2011-2021



## NUMBER OF TISSUES TRANSPLANTED BY PARTICIPATING PROVINCES, CTOSS 2020-2021\*

\*For Alberta, AB Health Services covers Northern Alberta regions.

### TISSUES TRANSPLANTED 2020-2021



**DESPITE AN INCREASED NUMBER OF TISSUES TRANSPLANTED IN 2020-2021, INCIDENCE RATES OF TAEs IN CANADA REMAIN LOW**

\*TAE: Any unintended or untoward medical occurrence that may be consequent or related to cells, tissues, or organs that are transplanted. An adverse event may be considered to be an incident or reaction.